Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Amarin Corporation PLC To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Amarin Corporation PLC (“Amarin” or the “Company”) (NASDAQ: AMRN) of the January 3, 2014 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against Amarin and certain executives.
A complaint has been filed on behalf of all persons who purchased Amarin common stock between July 9, 2009 and October 15, 2013 (the “Class Period”) in the District of New Jersey.
The complaint alleges that the Company and its executives violated federal securities laws with respect to its disclosures concerning its business, operations, and prospects.
Specifically, the action alleges that throughout the Class Period, Amarin issued false and/or misleading statements regarding the prospects of the FDA approving Vascepa, the Company’s lead product.
On October 16, 2013, Amarin announced that the FDA’s Endrocrinologic and Metabolic Drugs Advisory Committee had voted 9 to 2 against approval of Vascepa.
Following this news, the Company’s stock declined $3.16 per share, or over 61%, to close at $2.01 per share on October 17, 2013.
If you invested in Amarin stock or options between July 9, 2009 and October 15, 2013 and would like to discuss your legal rights, you can contact us by calling Richard Gonnello or Francis McConville toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to email@example.com or firstname.lastname@example.org. Faruqi & Faruqi, LLP also encourages anyone with information regarding Amarin’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.